EGFR and non-small cell lung carcinoma: The standard of care is platinum-based chemotherapy, with a median progression-free survival (mPFS) of 4.1 to 6.4 months and a response rate of 50% to 63%.[5–7] There is a significant clinical need to improve the outcome of NSCLC patients harboring EGFR ex20ins mutations.